Cornerstone Capital, Inc. Abb Vie Inc. Transaction History

Cornerstone Capital, Inc.

$1.06 Billion
Q3 2024

A detailed history of Cornerstone Capital, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Cornerstone Capital, Inc. holds 182,827 shares of ABBV stock, worth $32 Million. This represents 3.4% of its overall portfolio holdings.

Number of Shares

182,827

Previous 181,189 0.9%

Holding current value

$32 Million

Previous $31.1 Million 16.18%

% of portfolio

3.4%

Previous 3.15%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 30, 2024	BUY	$163.84 - $199.33 $268,369 - $326,502	1,638 Added 0.9%	182,827 $36.1 Million
Q2 2024 Aug 02, 2024	SELL	$154.79 - $180.76 $740,979 - $865,298	-4,787 Reduced 2.57%	181,189 $31.1 Million
Q1 2024 May 01, 2024	SELL	$159.82 - $182.1 $1.74 Million - $1.99 Million	-10,915 Reduced 5.54%	185,976 $33.9 Million
Q4 2023 Feb 02, 2024	SELL	$137.6 - $154.97 $156,038 - $175,735	-1,134 Reduced 0.57%	196,891 $30.5 Million
Q3 2023 Nov 13, 2023	SELL	$133.59 - $154.65 $495,752 - $573,906	-3,711 Reduced 1.84%	198,025 $29.5 Million
Q2 2023 Aug 21, 2023	BUY	$132.51 - $164.9 $78,710 - $97,950	594 Added 0.3%	201,736 $27.2 Million
Q1 2023 May 15, 2023	SELL	$144.61 - $166.54 $98,334 - $113,247	-680 Reduced 0.34%	201,142 $32.1 Million
Q4 2022 Feb 13, 2023	SELL	$138.31 - $165.87 $217,838 - $261,245	-1,575 Reduced 0.77%	201,822 $32.6 Million
Q3 2022 Oct 27, 2022	BUY	$134.21 - $153.93 $159,307 - $182,714	1,187 Added 0.59%	203,397 $27.3 Million
Q2 2022 Aug 15, 2022	SELL	$137.62 - $174.96 $679,567 - $863,952	-4,938 Reduced 2.38%	202,210 $31 Million
Q1 2022 May 13, 2022	SELL	$131.98 - $163.75 $2.68 Million - $3.33 Million	-20,319 Reduced 8.93%	207,148 $33.6 Million
Q4 2021 Feb 11, 2022	BUY	$107.43 - $135.93 $223,454 - $282,734	2,080 Added 0.92%	227,467 $30.8 Million
Q3 2021 Nov 09, 2021	BUY	$106.4 - $120.78 $346,332 - $393,138	3,255 Added 1.47%	225,387 $24.3 Million
Q2 2021 Aug 13, 2021	BUY	$105.21 - $117.21 $335,409 - $373,665	3,188 Added 1.46%	222,132 $25 Million
Q1 2021 May 17, 2021	BUY	$102.3 - $112.62 $480,093 - $528,525	4,693 Added 2.19%	218,944 $23.7 Million
Q4 2020 Feb 12, 2021	SELL	$80.49 - $108.67 $86,848 - $117,254	-1,079 Reduced 0.5%	214,251 $23 Million
Q3 2020 Oct 27, 2020	BUY	$85.91 - $100.83 $558,243 - $655,193	6,498 Added 3.11%	215,330 $18.9 Million
Q2 2020 Aug 14, 2020	BUY	$73.37 - $98.18 $249,824 - $334,302	3,405 Added 1.66%	208,832 $20.5 Million
Q1 2020 May 15, 2020	BUY	$64.5 - $97.79 $675,766 - $1.02 Million	10,477 Added 5.37%	205,427 $15.7 Million
Q4 2019 Feb 10, 2020	BUY	$72.13 - $90.25 $1.63 Million - $2.04 Million	22,637 Added 13.14%	194,950 $17.3 Million
Q3 2019 Nov 13, 2019	SELL	$62.98 - $75.72 $139,185 - $167,341	-2,210 Reduced 1.27%	172,313 $13 Million
Q2 2019 Aug 14, 2019	SELL	$65.7 - $83.98 $402,412 - $514,377	-6,125 Reduced 3.39%	174,523 $12.7 Million
Q1 2019 May 15, 2019	SELL	$77.14 - $90.79 $213,677 - $251,488	-2,770 Reduced 1.51%	180,648 $14.6 Million
Q4 2018 Feb 11, 2019	SELL	$77.85 - $96.01 $186,450 - $229,943	-2,395 Reduced 1.29%	183,418 $16.9 Million
Q3 2018 Nov 13, 2018	SELL	$88.91 - $98.84 $82,686 - $91,921	-930 Reduced 0.5%	185,813 $17.6 Million
Q2 2018 Aug 13, 2018	SELL	$89.78 - $106.23 $703,785 - $832,736	-7,839 Reduced 4.03%	186,743 $17.3 Million
Q1 2018 May 08, 2018	SELL	$92.01 - $123.21 $136,726 - $183,090	-1,486 Reduced 0.76%	194,582 $18.4 Million
Q4 2017 Feb 12, 2018	SELL	$89.56 - $98.21 $1.6 Million - $1.76 Million	-17,905 Reduced 8.37%	196,068 $19 Million
Q3 2017 Nov 13, 2017	BUY	$69.85 - $89.22 $14.9 Million - $19.1 Million	213,973	213,973 $19 Million

Others Institutions Holding ABBV

# of Institutions

3,855

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $310B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cornerstone Capital, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cornerstone Capital, Inc. with notifications on news.

Account

Cornerstone Capital, Inc. Abb Vie Inc. Transaction History